Trials / Not Yet Recruiting
Not Yet RecruitingNCT07523607
FAP PET/CT for Staging Patients With Breast Cancer
[⁶⁸Ga]Ga-FAP-2286 PET/CT for Staging and Restaging Patients With Newly Diagnosed Primary Breast Cancer: a Phase II Study (FAPILOUS)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Odense University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the clinical utility of \[68Ga\]Ga-FAP-2268 PET/CT for disease staging and assessment in patients with high-risk primary breast cancer. By targeting fibroblast activation protein (FAP), this novel imaging approach may offer improved tumor visualization compared to conventional imaging, which may help improve treatment planning.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-FAP-2286 | One scan at baseline staging, and for those reciving NACT : one scan before surgery. |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2028-01-01
- Completion
- 2029-01-01
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Source: ClinicalTrials.gov record NCT07523607. Inclusion in this directory is not an endorsement.